SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition.

[1]  C. Kruse,et al.  SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition, active in preclinical models for antipsychotic as well as anxiolytic activity , 2001, European Neuropsychopharmacology.

[2]  C. Kruse,et al.  New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities. , 2001, Bioorganic & medicinal chemistry letters.

[3]  H. Silver,et al.  Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo‐controlled study , 2000, International clinical psychopharmacology.

[4]  D. King.  Drug treatment of the negative symptoms of schizophrenia , 1998, European Neuropsychopharmacology.

[5]  C. Galletly,et al.  Relationships between changes in symptom ratings, neuropsychological test performance and quality of life in schizophrenic patients treated with clozapine , 1997, Psychiatry Research.

[6]  D. Goff,et al.  A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia , 1995, Psychopharmacology.

[7]  J. Hyttel,et al.  Selective, centrally acting serotonin 5-HT2 antagonists. 1. 2- and 6-substituted 1-phenyl-3-(4-piperidinyl)-1H-indoles. , 1992, Journal of medicinal chemistry.

[8]  L. D. Bradford,et al.  A rapidly acquired one-way conditioned avoidance procedure in rats as a primary screening test for antipsychotics: influence of shock intensity on avoidance performance , 1988, Behavioural Brain Research.

[9]  G. Le Fur,et al.  3-(4-Piperidinylalkyl)indoles, selective inhibitors of neuronal 5-hydroxytryptamine uptake. , 1980, Journal of medicinal chemistry.

[10]  B. Costall,et al.  Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. , 1978, European journal of pharmacology.

[11]  B. Jacobs,et al.  An animal behavior model for studying central serotonergic synapses. , 1976, Life sciences.

[12]  I. Gottesman,et al.  Schizophrenics kill themselves too: a review of risk factors for suicide. , 1990, Schizophrenia bulletin.

[13]  J. Guillaume,et al.  (Tétrahydro-1,2,3,6 pyridinyl-4)-3 1H-indoles: synthèse, propriétés sérotoninergique et anti-dopaminergiques , 1987 .